


**Amended Claims**

1. **(currently amended)** A method of preventing or inhibiting ~~solid tumor~~ **melanoma growth, lung carcinoma growth, or hypercalcemia** in a mammal, **wherein:**

the method **comprises** ~~comprising~~ administering to a mammal in need thereof a therapeutically effective amount of:

a compound **or pharmaceutically acceptable salt thereof, and**  
**a chemotherapeutic agent;**

**the compound corresponds in structure to [[of]] the formula:**









X and Y are **independently selected the same or different halo [[group]];**




R is H or lower alkyl; and ~~pharmaceutically acceptable salts thereof; together with a~~  
**the** chemotherapeutic agent **is** selected from the group consisting of cyclophosphamide, ~~methotrexate~~ **methotrexate**, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

**Claim 2. (canceled).**

3. **(previously presented)** A method according to claim 1 wherein the compound is selected from the group consisting of:








**Claim 4. (canceled).**

5. (currently amended) A method of preventing or inhibiting solid tumor melanoma growth, lung carcinoma growth, or hypercalcemia in a mammal, wherein:

the method comprises ~~comprising~~ administering to a mammal in need thereof a therapeutically effective amount of:

a compound or pharmaceutically acceptable salt thereof, and  
a chemotherapeutic agent;

the compound corresponds in structure to [[of]] the formula:






X and Y are independently selected the same or different halo [[group]];






R is H or lower alkyl; ~~and or a pharmaceutically acceptable salt thereof; together with a~~


the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, ~~methotrexate~~ methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

**Claim 6. (canceled).**

7. **(previously presented)** A method according to claim 5 wherein the compound is selected from the group consisting of:







8. (canceled).


9. (currently amended) A pharmaceutical composition, wherein:

the composition comprises: comprising

a therapeutically effective amount of a compound (or a pharmaceutically acceptable salt thereof) and a chemotherapeutic agent; and

a pharmaceutically acceptable carrier;

the compound corresponds in structure to [[of]] the formula:








X and Y are independently selected the same or different halo [[group]];






R is H or lower alkyl; and or a pharmaceutically acceptable salt thereof,

a chemotherapeutic agent selected from the group consisting of cyclophosphamide, ~~methotrexate~~ methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine ~~;~~ and ~~a pharmaceutically acceptable carrier.~~






Claims 10-13 (canceled).




14. (currently amended) A pharmaceutical composition as set forth in claim 9, wherein the ~~composition comprises a therapeutically effective amount of a~~ compound is selected from the group consisting of:











**Please add the following new claims:**

15. **(new)** A method according to claim 1, wherein melanoma growth is inhibited or prevented.

16. **(new)** A method according to claim 1, wherein lung carcinoma growth is inhibited or prevented.

17. **(new)** A method according to claim 1, wherein hypercalcemia is inhibited or prevented.

18. **(new)** A method according to claim 5, wherein melanoma growth is inhibited or prevented.


19. **(new)** A method according to claim 5, wherein lung carcinoma growth is inhibited or prevented.

20. **(new)** A method according to claim 5, wherein hypercalcemia is inhibited or prevented.

21. **(new)** A method according to claim 1, wherein the chemotherapeutic agent is cyclophosphamide.

22. **(new)** A method according to claim 5, wherein the chemotherapeutic agent is cyclophosphamide.

23. **(new)** A method according to claim 5, wherein the compound is:



24. **(new)** A method according to claim 23, wherein the chemotherapeutic agent is cyclophosphamide.

25. **(new)** A method according to claim 24, wherein melanoma growth is inhibited or prevented.

26. **(new)** A method according to claim 24, wherein lung carcinoma growth is inhibited or prevented.